title: Clinical trials update from the American Heart Association 2006: OAT, SALT 1 and 2, MAGIC, ABCD, PABA-CHF, IMPROVE-CHF, and percutaneous mitral annuloplasty.
abstract: This article provides information and a commentary on trials presented at the American Heart Association meeting held in November 2006, relevant to the pathophysiology, prevention and treatment of heart failure. All reports should be considered as preliminary data, as analyses may change in the final publication. The OAT study failed to show a benefit of PCI over optimal medical therapy in patients with persistent total occlusion of the infarct related artery following a myocardial infarction. In SALT 1 and 2, tolvaptan was found to correct hyponatraemia of various aetiologies; however, whether this has an impact on heart failure prognosis requires further evaluation. A placebo controlled study of myocardial implantation of skeletal myoblasts in patients with moderate to severe LVSD (MAGIC) showed equivocal/uncertain effects, long term follow-up data are awaited. The ABCD study which compared the ability of an invasive and a non-invasive test to identify patients at risk of arrhythmic events prior to ICD implantation, suggested that the two strategies were comparable, although the practical value of either test remains uncertain and the study had many major flaws. The PABA-CHF study hinted that pulmonary vein antrum isolation might be more effective than AV node ablation with bi-ventricular pacing for the treatment of patients with heart failure in atrial fibrillation. In IMPROVE-CHF, an NT-pro BNP guided treatment strategy was found to reduce the cost of managing patients with acute breathlessness.
authors.affiliation: Department of Cardiology, Postgraduate Medical Institute, Division of Cardiovascular and Respiratory Studies, University of Hull, Castle Hill Hospital, Cottingham, Kingston-upon-Hull, HU16 5JQ, UK.
authors.forename: John G F
authors.initials: JG
authors.lastname: Cleland
authors.forename: Alison P
authors.initials: AP
authors.lastname: Coletta
authors.forename: Ahmed Tageldien
authors.initials: AT
authors.lastname: Abdellah
authors.forename: Mansoor
authors.initials: M
authors.lastname: Nasir
authors.forename: Neil
authors.initials: N
authors.lastname: Hobson
authors.forename: Nick
authors.initials: N
authors.lastname: Freemantle
authors.forename: Andrew L
authors.initials: AL
authors.lastname: Clark
mesh_terms: D000573:American Hospital Association; D001157:Arterial Occlusive Diseases / Q000628:therapy; D001281:Atrial Fibrillation / Q000628:therapy; D009202:Cardiomyopathies / Q000628:therapy; D002986:Clinical Trials as Topic; D003331:Coronary Vessels; D004554:Electric Countershock; D019918:Heart Valve Prosthesis Implantation / Q000401:mortality / Q000592:standards*; D006801:Humans; D007010:Hyponatremia / Q000628:therapy; D008943:Mitral Valve; D032446:Myoblasts / Q000637:transplantation; D015203:Reproducibility of Results; D016019:Survival Analysis; D014182:Transplantation, Autologous; D014481:United States